The NIAGARA trial showed that adding durvalumab to neoadjuvant chemotherapy in MIBC patients did not negatively impact HRQOL outcomes. Significant improvement in event-free survival was observed with ...
The study investigators concluded that EV+P demonstrated activity in advanced urothelial carcinoma tumors with histologic ...
Follow-up was done according to EAU guidelines. In 27 patients mIR-371 was evaluated preoperatively and correlated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback